Lunai Bioworks (LNAI) Registration Filing summary

Company overview and business model

• Operates through subsidiaries focused on advanced cell/gene therapies and AI-driven cancer diagnostics.

• Biosciences arm develops allogeneic cell and gene therapies for cancer and infectious diseases, with a shift in focus to acquired GEDi Cube Intl technologies.

• AI subsidiary, Renovaro Cube, commercializes proprietary platforms for early cancer detection, recurrence monitoring, and personalized treatment selection.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates was approximately $111.9 million as of October 16, 2024.

• 161,717,342 shares of common stock issued and outstanding as of October 27, 2024.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, with broad discretion retained over allocation.